Investment in antimalarial drug development is bearing fruit

Front-line antimalarial drugs (the artemisinin-based combination therapies) are failing in southeast Asia, making the need for novel antimalarials more pressing than ever. In The Lancet Infectious Diseases, two studies of DSM265, a plasmodium dihydroorotate dehydrogenase inhibitor, are reported. Thi...